Abstracts related to ketamine therapy or biology will be considered for oral or poster presentation. Unpublished findings and reviews of clinical experience are welcome. ASKP invites submission of abstracts related to the use of ketamine, or related compounds, for the treatment of psychiatric conditions, pain, or substance use disorders. Abstracts should describe findings from clinical practice or research. Authors of selected abstracts will be invited to give 15 minute oral presentations, and the abstract will be printed in the conference proceedings. Not all abstracts can be selected. Selection criteria include novelty and significance for clinical practice. Abstracts must be submitted through the conference registration page by July 15, 2020 at 5pm Eastern Time. The abstract length is limited to 5000 characters.